AUTHOR=Tang Shan , Bai Li , Hou Wei , Hu Zhongjie , Chen Xinyue , Zhao Jing , Liang Chen , Zhang Wei , Duan Zhongping , Zheng Sujun 

TITLE=Comparison of the Effectiveness and Safety of d-Penicillamine and Zinc Salt Treatment for Symptomatic Wilson Disease: A Systematic Review and Meta‐Analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.847436

DOI=10.3389/fphar.2022.847436

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Pharmacological therapy is currently the main treatment method for patients with Wilson disease (WD). We aimed to evaluate the efficacy and safety of the common treatment regimens in these patients.</p><p><bold>Methods:</bold> We conducted a systemic review and meta-analysis by searching multiple databases for studies from inception to October 2021. Outcomes of interest were the improved rate and safety of <sc>d</sc>-penicillamine and zinc salts treatment in WD patients. Two independent reviewers performed the study selection and data extraction.</p><p><bold>Results:</bold> Sixteen studies were included in this meta-analysis. The pooled improved rate for all included symptomatic WD patients was 78.0% (95% CI: 70.8%–85.2%). In symptomatic hepatic WD patients, there is no difference in the treatment efficiency of <sc>d</sc>-penicillamine and zinc salts (RR: 0.98, 95% CI: 0.86%–1.12%; <italic>p</italic> = 0.765). In neurological WD patients, the pooled improved rate of those who received <sc>d</sc>-penicillamine and zinc salts was 56.3% (95% CI: 37.5%–75.1%) and 80.2% (95% CI: 67.2%–93.2%), respectively. The incidence of adverse effects (RR: 2.42, 95% CI: 1.20%–4.88%; <italic>p</italic> = 0.014) and neurological deterioration (RR: 1.96, 95% CI: 1.31%–2.93%; <italic>p</italic> = 0.001) in all symptomatic WD patients treated with <sc>d</sc>-penicillamine was both higher than that of patients treated with zinc salts.</p><p><bold>Conclusion:</bold> Our analysis suggests that symptomatic WD patients treated with <sc>d</sc>-penicillamine have higher incidence of adverse effects and neurological deterioration than that of zinc salts. The therapeutic effectiveness of these two regimens does not seem to be significantly different, and these results must be interpreted with caution.</p><p><bold>Systematic Review Registration</bold>: PROSPERO registration, identifier CRD 42021287126.</p>